Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies

Journal of Alzheimer's Disease

Volumn 62, Issue 3, 2018, Pages 965-992

  Martins, Ralph N ^a,b,c,d,e   Villemagne, Victor ^m,n   Sohrabi, Hamid R ^a,b,c,d,e,o   Chatterjee, Pratishtha ^a,c,e   Shah, Tejal M ^a,b,c   Verdile, Giuseppe ^a,b,f   Fraser, Paul ^r   Taddei, Kevin ^a,b,o   Gupta, Veer B ^a,o   Rainey Smith, Stephanie R ^a,b   Hone, Eugene ^a,o   Pedrini, Steve ^a,o   Lim, Wei Ling ^a   Martins, Ian ^a   Frost, Shaun ^h   Gupta, Sunil ^a,b,c,e   O'Bryant, Sid ^l   Rembach, Alan ⁿ   Ames, David ^p,q   Ellis, Kathryn ^p   Fuller, Stephanie J ^b   Brown, Belinda ^b,g   Gardener, Samantha L ^a,b   Fernando, Binosha ^a   Bharadwaj, Prashant ^a   Burnham, Samantha ^a,h   Laws, Simon M ^a,o   Barron, Anna M ^d,s   Goozee, Kathryn ^c,d,e,i,o   Wahjoepramono, Eka J ^a   Asih, Prita R ^e,j   Doecke, James D ^h   Salvado, Olivier ^h,o   Bush, Ashley I ^n,o   Rowe, Christopher C ^m,n   Gandy, Samuel E ^k   Masters, Colin L ^o   more..

^a EDITH COWAN UNIVERSITY   (Australia)

^b Ralph and Patricia Sarich Neuroscience Research Institute   (Australia)

^c MACQUARIE UNIVERSITY   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e KaRa Institute of Neurological Disease   (Australia)

^f CURTIN UNIVERSITY   (Australia)

^g MURDOCH UNIVERSITY   (Australia)

^h CSIRO   (Australia)

ⁱ Anglicare   (Australia)

^j UNIVERSITY OF NEW SOUTH WALES   (Australia)

^k MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF NORTH TEXAS   (United States)

^m AUSTIN HEALTH   (Australia)

ⁿ FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^o University of Melbourne   (Australia)

^p UNIVERSITY OF MELBOURNE   (Australia)

^q NATIONAL AGEING RESEARCH INSTITUTE   (Australia)

^r UNIVERSITY OF TORONTO   (Canada)

^s NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

more..

Author keywords

Alzheimer's disease; amyloid; apolipoprotein E; A ; biomarker; dementia; early diagnosis; preclinical

Indexed keywords

AMYLOID PROTEIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; INSULIN; TRACER;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; DIABETES MELLITUS; DIET; EYE EXAMINATION; HUMAN; INFLAMMATION; NEUROIMAGING; NONHUMAN; OXIDATIVE STRESS; PHYSICAL ACTIVITY; POSITRON EMISSION TOMOGRAPHY; PRECLINICAL STUDY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SLEEP; ANIMAL; AUSTRALIA; METABOLISM; PHYSIOLOGY;

ALZHEIMER DISEASE; AMYLOIDOGENIC PROTEINS; ANIMALS; AUSTRALIA; BIOMARKERS; HUMANS; OXIDATIVE STRESS;

EID: 85044368934     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-171145     Document Type: Review

References (236)

1. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI (1986) Abnormal phosphorylation of the microtubule-Associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad SciUSA 83, 4913-4917.
2. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM (1986) Microtubule-Associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 261, 6084-6089.
3. Masters CL, Multhaup G, Simms G, Pottgiesser J, Martins RN, Beyreuther K (1985) Neuronal origin of a cerebral amyloid: Neurofibrillary tangles of Alzheimers disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J 4, 2757-2763.
4. Davies L, Wolska B, Hilbich C, Multhaup G, Martins R, Simms G, Beyreuther K, Masters CL (1988) A4 amyloid protein deposition and the diagnosis of Alzheimers disease: Prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology 38, 1688-1693.
5. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 82, 4245-4249.
6. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Muller-Hill B (1987) The precursor of Alzheimers disease amyloid A4 protein resembles a cell-surface receptor. Nature 325, 733-736.
7. Hutton M, Perez-Tur J, Hardy J (1998) Genetics of Alzheimers disease. Essays Biochem 33, 117-131.
8. Verdile G, Keane KN, Cruzat VF, Medic S, Sabale M, Rowles J, Wijesekara N, Martins RN, Fraser PE, Newsholme P (2015) Inflammation and oxidative stress: The molecular connectivity between insulin resistance, obesity, and Alzheimers disease. Mediators Inflamm 2015, 105828.
9. Petersen RB, Nunomura A, Lee HG, Casadesus G, Perry G, Smith MA, Zhu X (2007) Signal transduction cascades associated with oxidative stress in Alzheimers disease. J Alzheimers Dis 11, 143-152.
10. Hardy JA, Higgins GA (1992) Alzheimers disease: The amyloid cascade hypothesis. Science 256, 184-185.
11. Musiek ES, Holtzman DM (2015) Three dimensions of the amyloid hypothesis: Time, space and wingmen. Nat Neurosci 18, 800-806.
12. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL, Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group (2013) Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimers disease: A prospective cohort study. Lancet Neurol 12, 357-367.
13. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimers disease: Recommendations from the National Institute on Aging-Alzheimers Associationworkgroups on diagnostic guidelines for Alzheimers disease. Alzheimers Dement 7, 280-292.
14. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K (1991) Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimers disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 541, 163-166.
15. Laws SM, Clarnette RM, Taddei K, Martins G, Paton A, Hallmayer J, Almeida OP, Groth DM, Gandy SE, Forstl H, Martins RN (2002) APOE-epsilon4 and APOE-491A polymorphisms in individuals with subjective memory loss. Mol Psychiatry 7, 768-775.
16. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD (1993) Apolipoprotein E: High-Avidity binding to beta-Amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 90, 1977-1981.
17. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ, et al. (1993) Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimers disease. Neurology 43, 1467-1472.
18. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimers disease in late onset families. Science 261, 921-923.
19. Martins RN, Clarnette R, Fisher C, Broe GA, Brooks WS, Montgomery P, Gandy SE (1995) ApoE genotypes in Australia: Roles in early and late onset Alzheimers disease and Downs syndrome. Neuroreport 6, 1513-1516.
20. Hone E, Martins IJ, Fonte J, Martins RN (2003) Apolipoprotein E influences amyloid-beta clearance from the murine periphery. J Alzheimers Dis 5, 1-8.
21. Sharman MJ, Morici M, Hone E, Berger T, Taddei K, Martins IJ, Lim WL, Singh S, Wenk MR, Ghiso J, Buxbaum JD, Gandy S, Martins RN (2010) APOE genotype results in differential effects on the peripheral clearance of amyloid-beta42 in APOE knock-in and knock-out mice. J Alzheimers Dis 21, 403-409.
22. Yang DS, Small DH, Seydel U, Smith JD, Hallmayer J, Gandy SE, Martins RN (1999) Apolipoprotein E promotes the binding and uptake of beta-Amyloid into Chinese hamster ovary cells in an isoform-specific manner. Neuroscience 90, 1217-1226.
23. Gudala K, Bansal D, Schifano F, Bhansali A (2013) Diabetes mellitus and risk of dementia: A meta-Analysis of prospective observational studies. J Diabetes Investig 4, 640-650.
24. Sellbom KS, Gunstad J (2012) Cognitive function and decline in obesity. J Alzheimers Dis 30(Suppl 2), S89-S95.
25. Gardener SL, Rainey-Smith SR, Martins RN (2016) Diet and inflammation in Alzheimers disease and related chronic diseases: A review. J Alzheimers Dis 50, 301-334.
26. Hazar N, Seddigh L, Rampisheh Z, Nojomi M (2016) Population attributable fraction of modifiable risk factors for Alzheimer disease: A systematic review of systematic reviews. Iran J Neurol 15, 164-172.
27. Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE (2012) Demonstrated brain insulin resistance in Alzheimers disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122, 1316-1338.
28. Mahley RW, HuangY, WeisgraberKH(2007) Detrimental effects of apolipoprotein E4: Potential therapeutic targets in Alzheimers disease. Curr Alzheimer Res 4, 537-540.
29. Watson WJ, Seiden HS (1984) Alzheimers disease: A current review. Can Fam Physician 30, 595-599.
30. Hall ED (1989) Free radicals and CNS injury. Crit Care Clin 5, 793-805.
31. Henke H, LangW(1983) Cholinergic enzymes in neocortex, hippocampus and basal forebrain of non-neurological and senile dementia of Alzheimer-Type patients. Brain Res 267, 281-291.
32. Kish SJ, Morito C, Hornykiewicz O (1985) Glutathione peroxidase activity in Parkinsons disease brain. Neurosci Lett 58, 343-346.
33. Martins RN, Harper CG, Stokes GB, Masters CL (1986) Increased cerebral glucose-6-phosphate dehydrogenase activity in Alzheimers disease may reflect oxidative stress. J Neurochem 46, 1042-1045.
34. Sultana R, Piroddi M, Galli F, Butterfield DA (2008) Protein levels and activity of some antioxidant enzymes in hippocampus of subjects with amnestic mild cognitive impairment. Neurochem Res 33, 2540-2546.
35. Gu F, Chauhan V, Chauhan A (2015) Glutathione redox imbalance in brain disorders. Curr Opin Clin Nutr Metab Care 18, 89-95.
36. Mandal PK, Tripathi M, Sugunan S (2012) Brain oxidative stress: Detection and mapping of anti-oxidant marker Glutathione in different brain regions of healthy male/female, MCI and Alzheimer patients using non-invasive magnetic resonance spectroscopy. Biochem Biophys Res Commun 417, 43-48.
37. Smith MA, Rottkamp CA, Nunomura A, Raina AK, Perry G(2000) Oxidative stress in Alzheimers disease. Biochim Biophys Acta 1502, 139-144.
38. Smith MA, Hirai K, Hsiao K, Pappolla MA, Harris PL, Siedlak SL, Tabaton M, Perry G (1998) Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 70, 2212-2215.
39. Gibson G, Martins R, Blass J, Gandy S (1996) Altered oxidation and signal transduction systems in fibroblasts from Alzheimer patients. Life Sci 59, 477-489.
40. Herrero-Mendez A, Almeida A, Fernandez E, Maestre C, Moncada S, Bolanos JP (2009) The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C-Cdh1. Nat Cell Biol 11, 747-752.
41. Johnson LA, Torres ER, Impey S, Stevens JF, Raber J (2017) Apolipoprotein E4 and insulin resistance interact to impair cognition and alter the epigenome and metabolome. Sci Rep 7, 43701.
42. Taddei K, Clarnette R, Gandy SE, Martins RN (1997) Increased plasma apolipoprotein E (apoE) levels in Alzheimers disease. Neurosci Lett 223, 29-32.
43. Rasmussen KL, Tybjaerg-Hansen A, Nordestgaard BG, Frikke-Schmidt R (2018) Plasma apolipoprotein E levels and risk of dementia-A Mendelian randomiza tion study of 106, 562 individuals. Alzheimers Dement 14, 71-80.
44. Yao J, Petanceska SS, Montine TJ, Holtzman DM, Schmidt SD, Parker CA, Callahan MJ, Lipinski WJ, Bisgaier CL, Turner BA, Nixon RA, Martins RN, Ouimet C, Smith JD, Davies P, Laska E, Ehrlich ME, Walker LC, Mathews PM, Gandy S (2004) Aging, gender and APOEisotype modulate metabolism of Alzheimers Abeta peptides and F-isoprostanes in the absence of detectable amyloid deposits. J Neurochem 90, 1011-1018.
45. Hone E, Martins IJ, Jeoung M, Ji TH, Gandy SE, Martins RN (2005) Alzheimers disease amyloid-beta peptide modulates apolipoprotein E isoform specific receptor binding. J Alzheimers Dis 7, 303-314.
46. Sharman MJ, Shui G, Fernandis AZ, Lim WL, Berger T, Hone E, Taddei K, Martins IJ, Ghiso J, Buxbaum JD, Gandy S, Wenk MR, Martins RN (2010) Profiling brain and plasma lipids in human APOE epsilon2, epsilon3, and epsilon4 knock-in mice using electrospray ionization mass spectrometry. J Alzheimers Dis 20, 105-111.
47. Lim WL, Lam SM, Shui G, Mondal A, Ong D, Duan X, Creegan R, Martins IJ, Sharman MJ, Taddei K, Verdile G, Wenk MR, Martins RN (2013) Effects of a high-fat, highcholesterol diet on brain lipid profiles in apolipoprotein E epsilon3 and epsilon4 knock-in mice. Neurobiol Aging 34, 2217-2224.
48. Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV(2008) apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest 118, 4002-4013.
49. Li J, Kanekiyo T, Shinohara M, Zhang Y, LaDu MJ, Xu H, Bu G (2012) Differential regulation of amyloidbeta endocytic trafficking and lysosomal degradation by apolipoprotein E isoforms. J Biol Chem 287, 44593-44601.
50. Small GW (1996) Neuroimaging and genetic assessment for early diagnosis of Alzheimers disease. J Clin Psychiatry 57(Suppl 14), 9-13.
51. Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D (1996) Preclinical evidence of Alzheimers disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 334, 752-758.
52. Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J (2001) Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimers disease. Proc Natl Acad Sci U S A 98, 3334-3339.
53. Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J (2005) Correlations between apolipoprotein E epsilon4 gene dose and brainimaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A 102, 8299-8302.
54. Rimajova M, Lenzo NP, Wu JS, Bates KA, Campbell A, Dhaliwal SS, McCarthy M, Rodrigues M, Paton A, Rowe C, Foster JK, Martins RN (2008) Fluoro-2-deoxy-D-glucose (FDG)-PET in APOEepsilon4 carriers in the Australian population. J Alzheimers Dis 13, 137-146.
55. Nielsen HM, Chen K, Lee W, Chen Y, Bauer RJ, 3rd, Reiman E, Caselli R, BuG(2017) Peripheral apoE isoform levels in cognitively normalAPOEepsilon3/epsilon4 individuals are associated with regional gray matter volume and cerebral glucose metabolism. Alzheimers Res Ther 9, 5.
56. Lautenschlager NT, Wu JS, Laws SM, Almeida OP, Clarnette RM, Joesbury K, Wagenpfeil S, Martins G, Paton A, Gandy SE, Forstl H, Martins RN (2005) Neurological soft signs are associated with APOE genotype, age and cognitive performance. J Alzheimers Dis 7, 325-330.
57. Ellis K, Ames D, Martins R, Hudson P, Masters C (2006) The Australian Biomarkers Lifestyle and Imaging flagship study of ageing. Acta Neuropsychiatr 18, 285.
58. Arab L, Sabbagh MN (2010) Are certain lifestyle habits associated with lower Alzheimers disease risk? J Alzheimers Dis 20, 785-794.
59. FaraGM(2015) Nutrition between sustainability and quality. Ann Ig 27, 693-704.
60. Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P, Lautenschlager NT, Lenzo N, Martins RN, Maruff P, Masters C, Milner A, Pike K, Rowe C, Savage G, Szoeke C, Taddei K, Villemagne V, Woodward M, Ames D, AIBL Research Group (2009) The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: Methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimers disease. Int Psychogeriatr 21, 672-687.
61. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B (2004) Imaging brain amyloid in Alzheimers disease with Pittsburgh Compound-B. Ann Neurol 55, 306-319.
62. Ellis KA, Rowe CC, Villemagne VL, Martins RN, Masters CL, Salvado O, Szoeke C, Ames D, AIBL Research Group (2010) Addressing population aging and Alzheimers disease through the Australian imaging biomarkers and lifestyle study: Collaboration with the Alzheimers Disease Neuroimaging Initiative. Alzheimers Dement 6, 291-296.
63. Chetelat G, Villemagne VL, Bourgeat P, Pike KE, Jones G, Ames D, Ellis KA, Szoeke C, Martins RN, OKeefe GJ, Salvado O, Masters CL, Rowe CC, Australian Imaging Biomarkers and Lifestyle Research Group (2010) Relationship between atrophy and beta-Amyloid deposition in Alzheimer disease. Ann Neurol 67, 317-324.
64. Foster JK, Albrecht MA, Savage G, Lautenschlager NT, Ellis KA, Maruff P, Szoeke C, Taddei K, Martins R, Masters CL, Ames D, AIBL Research Group (2013) Lack of reliable evidence for a distinctive epsilon4-related cognitive phenotype that is independent from clinical diagnostic status: Findings from the Australian Imaging, Biomarkers and Lifestyle Study. Brain 136, 2201-2216.
65. Lim YY, Villemagne VL, Pietrzak RH, Ames D, Ellis KA, Harrington K, Snyder PJ, Martins RN, Masters CL, Rowe CC, Maruff P, Australian Imaging Biomarkers and Lifestyle Research Group (2015) APOE epsilon4 moderates amyloid-related memory decline in preclinical Alzheimers disease. Neurobiol Aging 36, 1239-1244.
66. Thai C, Lim YY, Villemagne VL, Laws SM, Ames D, Ellis KA, Rainey-Smith SR, Martins RN, Masters CL, Rowe CC, Maruff P, Australian Imaging Biomarkers and Lifestyle Research Group (2015) Amyloid-related memory decline in preclinical Alzheimers disease is dependent onAPOEepsilon4 and is detectable over 18-months. PLoS One 10, e0139082.
67. Albrecht MA, Szoeke C, Maruff P, Savage G, Lautenschlager NT, Ellis KA, Taddei K, Martins R, Masters CL, Ames D, Foster JK, AIBL Research Group (2015) Longi tudinal cognitive decline in the AIBL cohort: The role of APOE epsilon4 status. Neuropsychologia 75, 411-419.
68. Zwan MD, Villemagne VL, Dore V, Buckley R, Bourgeat P, Veljanoski R, Salvado O, Williams R, Margison L, Rembach A, Macaulay SL, Martins R, Ames D, van der Flier WM, Ellis KA, Scheltens P, Masters CL, Rowe CC (2016) Subjective memory complaints in APOE epsilon4 carriers are associated with high amyloid-beta burden. J Alzheimers Dis 49, 1115-1122.
69. Lim YY, Laws SM, Villemagne VL, Pietrzak RH, Porter T, Ames D, Fowler C, Rainey-Smith S, Snyder PJ, Martins RN, Salvado O, Bourgeat P, Rowe CC, Masters CL, Maruff P (2016) Abeta-related memory decline in APOE epsilon4 noncarriers: Implications for Alzheimer disease. Neurology 86, 1635-1642.
70. Hollands S, Lim YY, Laws SM, Villemagne VL, Pietrzak RH, Harrington K, Porter T, Snyder P, Ames D, Fowler C, Rainey-Smith SR, Martins RN, Salvado O, Robertson J, Rowe CC, Masters CL, Maruff P, AIBL Research Group (2017) APOEepsilon4 genotype, amyloid, and clinical disease progression in cognitively normal older adults. J Alzheimers Dis 57, 411-422.
71. Lim YY, Williamson R, Laws SM, Villemagne VL, Bourgeat P, Fowler C, Rainey-Smith S, Salvado O, Martins RN, Rowe CC, Masters CL, Maruff P, AIBL Research Group (2017) Effect of APOE genotype on amyloid deposition, brain volume, and memory in cognitively normal older individuals. J Alzheimers Dis 58, 1293-1302.
72. Liao F, Yoon H, Kim J (2017) Apolipoprotein E metabolism and functions in brain and its role in Alzheimers disease. Curr Opin Lipidol 28, 60-67.
73. Huang Y, Mahley RW (2014) Apolipoprotein E: Structure and function in lipid metabolism, neurobiology, and Alzheimers diseases. Neurobiol Dis 72 Pt A 3-12.
74. Ulrich JD, Holtzman DM (2016) TREM2 function in Alzheimers disease and neurodegeneration. ACS Chem Neurosci 7, 420-427.
75. Zhang Y, Tang HQ, Peng WJ, Zhang BB, Liu M (2015) Meta-Analysis for the association of apolipoprotein E epsilon2/epsilon3/epsilon4 polymorphism with coronary heart disease. Chin Med J (Engl) 128, 1391-1398.
76. Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, Soares H, Simon AJ, Lewczuk P, Dean RA, Siemers E, Potter W, Lee VM, Trojanowski JQ, Alzheimers Disease Neuroimaging Initiative (2011) Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol 121, 597-609.
77. Asih PR, Chatterjee P, Verdile G, Gupta VB, Trengove RD, Martins RN (2014) Clearing the amyloid in Alzheimers: Progress towards earlier diagnosis and effective treatments-An update for clinicians. Neurodegener Dis Manag 4, 363-378.
78. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon-Danguy H, Morandeau L, OKeefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31, 1275-1283.
79. Lim YY, Ellis KA, Harrington K, Pietrzak RH, Gale J, Ames D, Bush AI, Darby D, Martins RN, Masters CL, Rowe CC, Savage G, Szoeke C, Villemagne VL, Maruff P (2013) Cognitive decline in adults with amnestic mild cognitive impairment and high amyloid-beta: Prodromal Alzheimers disease? J Alzheimers Dis 33, 1167-1176.
80. Lim YY, Pietrzak RH, Ellis KA, Jaeger J, Harrington K, Ashwood T, Szoeke C, Martins RN, Bush AI, Masters CL, Rowe CC, Villemagne VL, Ames D, Darby D, Maruff P (2013) Rapid decline in episodic memory in healthy older adults with high amyloid-beta. J Alzheimers Dis 33, 675-679.
81. Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourgeat P, Ackermann U, Jones G, Szoeke C, Salvado O, Martins R, OKeefe G, Mathis CA, Klunk WE, Ames D, Masters CL, Rowe CC (2011) Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 69, 181-192.
82. Rowe CC, Bourgeat P, Ellis KA, Brown B, Lim YY, Mulligan R, Jones G, Maruff P, Woodward M, Price R, Robins P, Tochon-Danguy H, OKeefe G, Pike KE, Yates P, Szoeke C, Salvado O, Macaulay SL, OMeara T, Head R, Cobiac L, Savage G, Martins R, Masters CL, Ames D, Villemagne VL (2013) Predicting Alzheimer disease with beta-Amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing. Ann Neurol 74, 905-913.
83. Chetelat G, Villemagne VL, Villain N, Jones G, Ellis KA, Ames D, Martins RN, Masters CL, Rowe CC, AIBL Research Group (2012) Accelerated cortical atrophy in cognitively normal elderly with high beta-Amyloid deposition. Neurology 78, 477-484.
84. Dore V, Villemagne VL, Bourgeat P, Fripp J, Acosta O, Chetelat G, Zhou L, Martins R, Ellis KA, Masters CL, Ames D, Salvado O, Rowe CC (2013) Cross-sectional and longitudinal analysis of the relationship between Abeta deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease. JAMA Neurol 70, 903-911.
85. Chetelat G, Villemagne VL, Pike KE, Ellis KA, Bourgeat P, Jones G, OKeefe GJ, Salvado O, Szoeke C, Martins RN, Ames D, Masters CL, Rowe CC, Australian Imaging Biomarkers and Lifestyle Study of ageing (AIBL) Research Group (2011) Independent contribution of temporal beta-Amyloid deposition to memory decline in the pre-dementia phase of Alzheimers disease. Brain 134, 798-807.
86. Villain N, Chetelat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, Ames D, Martins RN, Eustache F, Salvado O, Masters CL, Rowe CC, Villemagne VL, AIBL Research Group (2012) Regional dynamics of amyloid-beta deposition in healthy elderly, mild cognitive impairment and Alzheimers disease: A voxelwise PiB-PET longitudinal study. Brain 135, 2126-2139.
87. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC, Dominantly Inherited Alzheimer Network (2012) Clinical and biomarker changes in dominantly inherited Alzheimers disease. N Engl J Med 367, 795-804.
88. Benzinger TL, Blazey T, Jack CR Jr, Koeppe RA, Su Y, Xiong C, Raichle ME, Snyder AZ, Ances BM, Bateman RJ, Cairns NJ, Fagan AM, Goate A, Marcus DS, Aisen PS, Christensen JJ, Ercole L, Hornbeck RC, Farrar AM, Aldea P, Jasielec MS, Owen CJ, Xie X, Mayeux R, Brickman A, McDade E, Klunk W, Mathis CA, Ringman J, Thomp son PM, Ghetti B, Saykin AJ, Sperling RA, Johnson KA, Salloway S, Correia S, Schofield PR, Masters CL, Rowe C, Villemagne VL, Martins R, Ourselin S, Rossor MN, Fox NC, Cash DM, Weiner MW, Holtzman DM, Buckles VD, Moulder K, Morris JC (2013) Regional variability of imaging biomarkers in autosomal dominant Alzheimers disease. Proc Natl Acad Sci U S A 110, E4502-E4509.
89. Li QX, Villemagne VL, Doecke JD, Rembach A, Sarros S, Varghese S, McGlade A, Laughton KM, Pertile KK, Fowler CJ, Rumble RL, Trounson BO, Taddei K, Rainey-Smith SR, Laws SM, Robertson JS, Evered LA, Silbert B, Ellis KA, Rowe CC, Macaulay SL, Darby D, Martins RN, Ames D, Masters CL, Collins S, AIBL Research Group (2015) Alzheimers disease normative cerebrospinal fluid biomarkers validated in PET amyloid-beta characterized subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. J Alzheimers Dis 48, 175-187.
90. Roberts BR, Lind M, Wagen AZ, Rembach A, FrugierT, Li QX, Ryan TM, McLean CA, Doecke JD, Rowe CC, Villemagne VL, Masters CL (2017) Biochemically-defined pools of amyloid-beta in sporadic Alzheimers disease: Correlation with amyloid PET. Brain 140, 1486-1498.
91. Doecke JD, Laws SM, Faux NG, WilsonW, Burnham SC, Lam CP, Mondal A, Bedo J, Bush AI, Brown B, De Ruyck K, Ellis KA, Fowler C, Gupta VB, Head R, Macaulay SL, Pertile K, Rowe CC, Rembach A, Rodrigues M, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ames D, Masters CL, Martins RN, Alzheimers Disease Neuroimaging Initiative, Australian Imaging Biomarkers and Lifestyle Research Group (2012) Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol 69, 1318-1325.
92. Burnham SC, Faux NG, Wilson W, Laws SM, Ames D, Bedo J, Bush AI, Doecke JD, Ellis KA, Head R, Jones G, Kiiveri H, Martins RN, Rembach A, Rowe CC, Salvado O, Macaulay SL, Masters CL, Villemagne VL, Alzheimers Disease Neuroimaging Initiative, Australian Imaging Biomarkers and Lifestyle Research Group (2014) A blood-based predictor for neocortical Abeta burden in Alzheimers disease: Results from the AIBL study. Mol Psychiatry 19, 519-526.
93. Burnham SC, Rowe CC, Baker D, Bush AI, Doecke JD, Faux NG, Laws SM, Martins RN, Maruff P, Macaulay SL, Rainey-Smith S, Savage G, Ames D, Masters CL, Wilson W, Villemagne VL (2016) Predicting Alzheimer disease from a blood-based biomarker profile:A54-month followup. Neurology 87, 1093-1101.
94. OBryant SE, Waring SC, Cullum CM, Hall J, Lacritz L, Massman PJ, Lupo PJ, Reisch JS, Doody R, Texas Alzheimers Research Consortium (2008) Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: A Texas Alzheimers research consortium study. Arch Neurol 65, 1091-1095.
95. Jack CR Jr, Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, Kantarci K, Gunter JL, Senjem ML, Ivnik RJ, Roberts RO, Rocca WA, Boeve BF, Petersen RC (2012) An operational approach to National Institute on Aging-Alzheimers Association criteria for preclinical Alzheimer disease. Ann Neurol 71, 765-775.
96. Jack CR Jr, Knopman DS, Chetelat G, Dickson D, Fagan AM, Frisoni GB, JagustW, Mormino EC, Petersen RC, Sperling RA, van der Flier WM, Villemagne VL, Visser PJ, Vos SJ (2016) Suspected non-Alzheimer disease pathophysiology-concept and controversy. Nat Rev Neurol 12, 117-124.
97. van HartenAC, Smits LL, Teunissen CE, Visser PJ, Koene T, Blankenstein MA, Scheltens P, van der FlierWM(2013) Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology 81, 1409-1416.
98. Rabinovici GD, Furst AJ, Alkalay A, Racine CA, ONeil JP, Janabi M, Baker SL, Agarwal N, Bonasera SJ, Mormino EC, Weiner MW, Gorno-Tempini ML, Rosen HJ, Miller BL, Jagust WJ (2010) Increased metabolic vulnerability in early-onset Alzheimers disease is not related to amyloid burden. Brain 133, 512-528.
99. Sojkova J, Resnick SM (2011) In vivo human amyloid imaging. Curr Alzheimer Res 8, 366-372.
100. Sperling RA, JackCRJr, Aisen PS (2011) Testing the right target and right drug at the right stage. Sci Transl Med 3, 111cm133.
101. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, GrundmanM(2010) 11CPiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimers disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9, 363-372.
102. Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, Klunk WE, Ashford E, Yoo K, Xu ZX, Loetscher H, Santarelli L (2012) Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 69, 198-207.
103. Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Sr., Jagust WJ, Johnson KA, Mathis CA, Minhas D, Pontecorvo MJ, Rowe CC, Skovronsky DM, Mintun MA (2015) The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement 11, 1-15 e11-14.
104. Rowe CC, Jones G, Dore V, Pejoska S, Margison L, Mulligan RS, Chan JG, Young K, Villemagne VL (2016) Standardized expression of 18F-NAV4694 and 11C-PiB beta-Amyloid PET results with the Centiloid scale. J Nucl Med 57, 1233-1237.
105. Rowe CC, Dore V, Jones G, Baxendale D, Mulligan RS, Bullich S, Stephens AW, De Santi S, Masters CL, Dinkelborg L, Villemagne VL (2017) 18F-Florbetaben PET beta-Amyloid binding expressed in Centiloids. Eur J Nucl Med Mol Imaging 44, 2053-2059.
106. FaganAM, Xiong C, JasielecMS, Bateman RJ, GoateAM, Benzinger TL, Ghetti B, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Salloway S, Schofield PR, Sperling RA, Marcus D, Cairns NJ, Buckles VD, Ladenson JH, Morris JC, Holtzman DM, Dominantly Inherited Alzheimer Network (2014) Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimers disease. Sci Transl Med 6, 226ra230.
107. Wang F, Gordon BA, Ryman DC, Ma S, Xiong C, Hassenstab J, Goate A, Fagan AM, Cairns NJ, Marcus DS, McDade E, Ringman JM, Graff-Radford NR, Ghetti B, Farlow MR, Sperling R, Salloway S, Schofield PR, Masters CL, Martins RN, Rossor MN, Jucker M, Danek A, Forster S, Lane CA, Morris JC, Benzinger TL, Bateman RJ, Dominantly Inherited Alzheimer Network (2015) Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. Neurology 85, 790-798.
108. Lee S, Viqar F, Zimmerman ME, Narkhede A, Tosto G, Benzinger TL, Marcus DS, Fagan AM, Goate A, Fox NC, Cairns NJ, Holtzman DM, Buckles V, Ghetti B, McDade E, Martins RN, Saykin AJ, Masters CL, Ringman JM, Ryan NS, Forster S, Laske C, Schofield PR, Sperling RA, Salloway S, Correia S, Jack C Jr, Weiner M, Bateman RJ, Morris JC, Mayeux R, Brickman AM, Dominantly Inherited Alzheimer Network (2016) White matter hyperintensities are a core feature of Alzheimers disease: Evidence from the dominantly inherited Alzheimer network. Ann Neurol 79, 929-939.
109. Muller S, Preische O, Sohrabi HR, Graber S, Jucker M, Dietzsch J, Ringman JM, Martins RN, McDade E, Schofield PR, Ghetti B, Rossor M, Graff-Radford NR, Levin J, GalaskoD, Quaid KA, Salloway S, Xiong C, Benzinger T, Buckles V, Masters CL, Sperling R, Bateman RJ, Morris JC, Laske C (2017) Decreased body mass index in the preclinical stage of autosomal dominant Alzheimers disease. Sci Rep 7, 1225.
110. Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144.
111. Niemantsverdriet E, Valckx S, Bjerke M, Engelborghs S (2017) Alzheimers disease CSF biomarkers: Clinical indications and rational use. Acta Neurol Belg 117, 591-602.
112. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM (2003) Decreased betaamyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA289, 2094-2103.
113. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K (2001) Evaluation of CSF-Tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58, 373-379.
114. Engelborghs S, De Vreese K, Van de Casteele T, Vanderstichele H, Van Everbroeck B, Cras P, Martin JJ, Vanmechelen E, De Deyn PP (2008) Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging 29, 1143-1159.
115. Hansson O, ZetterbergH, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimers disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol 5, 228-234.
116. Ray S, Britschgi M, Herbert C, Takeda-UchimuraY, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T (2007) Classification and prediction of clinical Alzheimers diagnosis based on plasma signaling proteins. Nat Med 13, 1359-1362.
117. Gomez Ravetti M, Moscato P (2008) Identification of a 5-protein biomarker molecular signature for predicting Alzheimers disease. PLoS One 3, e3111.
118. Bjorkqvist M, Ohlsson M, Minthon L, Hansson O (2012) Evaluation of a previously suggested plasma biomarker panel to identify Alzheimers disease. PLoS One 7, e29868.
119. Marksteiner J, Kemmler G, Weiss EM, Knaus G, Ullrich C, Mechtcheriakov S, Oberbauer H, Auffinger S, Hinterholzl J, Hinterhuber H, Humpel C (2011) Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimers disease. Neurobiol Aging 32, 539-540.
120. OBryant SE, Xiao G, Barber R, Huebinger R, Wilhelmsen K, Edwards M, Graff-Radford N, Doody R, Diaz-Arrastia R, Texas Alzheimers Research & Care Consortium; Alzheimers Disease Neuroimaging Initiative (2011) A blood-based screening tool for Alzheimers disease that spans serum and plasma: Findings from TARC and ADNI. PLoS One 6, e28092.
121. Soares HD, Potter WZ, Pickering E, Kuhn M, Immermann FW, Shera DM, Ferm M, Dean RA, Simon AJ, Swenson F, Siuciak JA, Kaplow J, Thambisetty M, Zagouras P, Koroshetz WJ, Wan HI, Trojanowski JQ, Shaw LM, Biomarkers Consortium Alzheimers Disease Plasma Proteomics Project (2012) Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch Neurol 69, 1310-1317.
122. Hu WT, Holtzman DM, Fagan AM, Shaw LM, Perrin R, Arnold SE, Grossman M, Xiong C, Craig-Schapiro R, Clark CM, Pickering E, Kuhn M, Chen Y, Van Deerlin VM, McCluskey L, Elman L, Karlawish J, Chen-Plotkin A, Hurtig HI, Siderowf A, Swenson F, Lee VM, Morris JC, Trojanowski JQ, Soares H, Alzheimers Disease Neuroimaging Initiative (2012) Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology 79, 897-905.
123. Johnstone D, Milward EA, Berretta R, Moscato P, Alzheimers Disease Neuroimaging Initiative (2012) Multivariate protein signatures of pre-clinical Alzheimers disease in the Alzheimers disease neuroimaging initiative (ADNI) plasma proteome dataset. PLoS One 7, e34341.
124. OBryant SE, Xiao G, Edwards M, Devous M, Gupta VB, Martins R, Zhang F, Barber R, Texas Alzheimers Research and Care Consortium (TARCC) (2013) Biomarkers of Alzheimers disease among Mexican Americans. J Alzheimers Dis 34, 841-849.
125. Pedrini S, Gupta VB, Hone E, Doecke J, OBryant S, James I, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Martins RN, AIBL Research Group (2017) A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of beta-Amyloid load in an AD cohort. Sci Rep 7, 14057.
126. Bates KA, Sohrabi HR, Rodrigues M, Beilby J, Dhaliwal SS, Taddei K, Criddle A, Wraith M, Howard M, Martins G, Paton A, Mehta P, Foster JK, Martins IJ, Lautenschlager NT, Mastaglia FL, Laws SM, Gandy SE, Martins RN (2009) Association of cardiovascular factors and Alzheimers disease plasma amyloid-beta protein in subjective memory complainers. J Alzheimers Dis 17, 305-318.
127. Chatterjee P, Lim WL, Shui G, Gupta VB, James I, Fagan AM, Xiong C, Sohrabi HR, Taddei K, Brown BM, BenzingerT, Masters C, Snowden SG, WenkMR, Bateman RJ, Morris JC, Martins RN (2016) Plasma phospholipid and sphingolipid alterations in presenilin1 mutation carriers: A pilot study. J Alzheimers Dis 50, 887-894.
128. Goozee K, Chatterjee P, James I, Shen K, Sohrabi HR, Asih PR, Dave P, Ball B, ManYan C, Taddei K, Chung R, Garg ML, Martins RN (2017) Alterations in erythrocyte fatty acid composition in preclinical Alzheimers disease. Sci Rep 7, 676.
129. Lui JK, Laws SM, Li QX, Villemagne VL, Ames D, Brown B, Bush AI, De Ruyck K, Dromey J, Ellis KA, Faux NG, Foster J, Fowler C, Gupta V, Hudson P, Laughton K, Masters CL, Pertile K, Rembach A, Rimajova M, Rodrigues M, Rowe CC, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ward V, Martins RN, AIBL Research Group (2010) Plasma amyloid-beta as a biomarker in Alzheimers disease: The AIBL study of aging. J Alzheimers Dis 20, 1233-1242.
130. Gupta VB, Laws SM, Villemagne VL, Ames D, Bush AI, Ellis KA, Lui JK, Masters C, Rowe CC, Szoeke C, Taddei K, Martins RN, AIBL Research Group (2011) Plasma apolipoprotein E and Alzheimer disease risk: The AIBL study of aging. Neurology 76, 1091-1098.
131. Gupta VB, Wilson AC, Burnham S, Hone E, Pedrini S, Laws SM, Lim WL, Rembach A, Rainey-Smith S, Ames D, Cobiac L, Macaulay SL, Masters CL, Rowe CC, Bush AI, Martins RN, AIBL Research Group (2015) Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort. Alzheimers Res Ther 7, 16.
132. Rembach A, Faux NG, Watt AD, Pertile KK, Rumble RL, Trounson BO, Fowler CJ, Roberts BR, Perez KA, Li QX, Laws SM, Taddei K, Rainey-Smith S, Robertson JS, Vandijck M, Vanderstichele H, Barnham KJ, Ellis KA, Szoeke C, Macaulay L, Rowe CC, Villemagne VL, Ames D, Martins RN, Bush AI, Masters CL, AIBL Research Group (2014) Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimers disease. Alzheimers Dement 10, 53-61.
133. Rembach A, Watt AD, Wilson WJ, Villemagne VL, Burnham SC, Ellis KA, Maruff P, Ames D, Rowe CC, Macaulay SL, Bush AI, Martins RN, Masters CL, Doecke JD, AIBL Research Group (2014) Plasma amyloid-beta levels are significantly associated with a transition toward Alzheimers disease as measured by cognitive decline and change in neocortical amyloid burden. J Alzheimers Dis 40, 95-104.
134. Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, Sullivan M, Paumier K, Holtzman DM, Morris JC, Benzinger T, Fagan AM, Patterson BW, Bateman RJ (2017) Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement 13, 841-849.
135. McCaddon A, Hudson P, Davies G, Hughes A, Williams JH, Wilkinson C (2001) Homocysteine and cognitive decline in healthy elderly. Dement Geriatr Cogn Disord 12, 309-313.
136. Kalmijn S, Launer LJ, Lindemans J, Bots ML, Hofman A, Breteler MM (1999) Total homocysteine and cognitive decline in a community-based sample of elderly subjects: The Rotterdam Study. Am J Epidemiol 150, 283-289.
137. Faux NG, Ellis KA, Porter L, Fowler CJ, Laws SM, Martins RN, Pertile KK, Rembach A, Rowe CC, Rumble RL, Szoeke C, Taddei K, Taddei T, Trounson BO, Villemagne VL, Ward V, Ames D, Masters CL, Bush AI (2011) Homocysteine, vitamin B12, and folic acid levels in Alzheimers disease, mild cognitive impairment, and healthy elderly: Baseline characteristics in subjects of the Australian Imaging Biomarker Lifestyle study. J Alzheimers Dis 27, 909-922.
138. Moore EM, Ames D, Mander AG, Carne RP, Brodaty H, Woodward MC, Boundy K, Ellis KA, Bush AI, Faux NG, Martins RN, Masters CL, Rowe CC, Szoeke C, Watters DA (2014) Among vitamin B12 deficient older people, high folate levels are associated with worse cognitive function: Combined data from three cohorts. J Alzheimers Dis 39, 661-668.
139. Patton N, Aslam T, Macgillivray T, Pattie A, Deary IJ, Dhillon B (2005) Retinal vascular image analysis as a potential screening tool for cerebrovascular disease: A rationale based on homology between cerebral and retinal microvasculatures. J Anat 206, 319-348.
140. Shah TM, Gupta SM, Chatterjee P, Campbell M, Martins RN (2017) Beta-Amyloid sequelae in the eye: A critical review on its diagnostic significance and clinical relevance in Alzheimers disease. Mol Psychiatry 22, 353-363.
141. Frost S, Martins RN, Kanagasingam Y (2010) Ocular biomarkers for early detection of Alzheimers disease. J Alzheimers Dis 22, 1-16.
142. Lim JK, Li QX, He Z, Vingrys AJ, Wong VH, Currier N, Mullen J, Bui BV, Nguyen CT (2016) The eye as a biomarker for Alzheimers disease. Front Neurosci 10, 536.
143. Frost SM, Kanagasingam Y, Sohrabi HR, Taddei K, Bateman R, Morris J, Benzinger T, Goate A, Masters CL, Martins RN (2013) Pupil response biomarkers distinguish amyloid precursor protein mutation carriers from noncarriers. Curr Alzheimer Res 10, 790-796.
144. Hou RH, Samuels ER, Raisi M, Langley RW, Szabadi E, Bradshaw CM (2006) Why patients with Alzheimers disease may show increased sensitivity to tropicamide eye drops: Role of locus coeruleus. Psychopharmacology (Berl) 184, 95-106.
145. Cheung CY, Ong YT, Hilal S, Ikram MK, Low S, Ong YL, Venketasubramanian N, Yap P, Seow D, Chen CL, Wong TY (2015) Retinal ganglion cell analysis using high-definition optical coherence tomography in patients with mild cognitive impairment and Alzheimers disease. J Alzheimers Dis 45, 45-56.
146. Pircher M, Hitzenberger CK, Schmidt-Erfurth U (2011) Polarization sensitive optical coherence tomography in the human eye. Prog Retin Eye Res 30, 431-451.
147. Gharbiya M, Trebbastoni A, Parisi F, Manganiello S, Cruciani F, Dantonio F, De Vico U, Imbriano L, Campanelli A, De Lena C (2014) Choroidal thinning as a new finding in Alzheimers disease: Evidence from enhanced depth imaging spectral domain optical coherence tomography. J Alzheimers Dis 40, 907-917.
148. Feke GT, Hyman BT, Stern RA, Pasquale LR (2015) Retinal blood flow in mild cognitive impairment and Alzheimers disease. Alzheimers Dement (Amst) 1, 144-151.
149. Frost S, Kanagasingam Y, Sohrabi H, Vignarajan J, Bourgeat P, Salvado O, Villemagne V, Rowe CC, Macaulay SL, Szoeke C, Ellis KA, Ames D, Masters CL, Rainey-Smith S, Martins RN, AIBL Research Group (2013) Retinal vascular biomarkers for early detection and monitoring of Alzheimers disease. Transl Psychiatry 3, e233.
150. Golzan SM, Goozee K, Georgevsky D, Avolio A, Chatterjee P, Shen K, Gupta V, Chung R, Savage G, Orr CF, Martins RN, Graham SL (2017) Retinal vascular and structural changes are associated with amyloid burden in the elderly: Ophthalmic biomarkers of preclinical Alzheimers disease. Alzheimers Res Ther 9, 13.
151. Frost S, Guymer R, Aung KZ, Macaulay SL, Sohrabi HR, Bourgeat P, Salvado O, Rowe CC, Ames D, Masters CL, Martins RN, Kanagasingam Y, AIBL Research Group (2016) Alzheimers disease and the early signs of age-related macular degeneration. Curr Alzheimer Res 13, 1259-1266.
152. Frost S, Bhuiyan A, Offerman D, Doecke JD, Macaulay SL, Sohrabi HR, Ames D, Masters C, Martins RN, Kanagasingam Y, AIBL Research Group (2017) Modulation of retinal arteriolar central reflection by APOE genotype. Curr Alzheimer Res 14, 916-923.
153. Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, Miller CA, Ko MK, Black KL, Schwartz M, Farkas DL (2011) Identification of amyloid plaques in retinas from Alzheimers patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage 54(Suppl 1), S204-S217.
154. More SS, Beach JM, Vince R (2016) Early Detection of amyloidopathy in Alzheimers mice by hyperspectral endoscopy. Invest Ophthalmol Vis Sci 57, 3231-3238.
155. Goldstein LE, Muffat JA, Cherny RA, Moir RD, Ericsson MH, Huang X, Mavros C, Coccia JA, Faget KY, Fitch KA, Masters CL, Tanzi RE, Chylack LT Jr, Bush AI (2003) Cytosolic beta-Amyloid deposition and supranuclear cataracts in lenses from people with Alzheimers disease. Lancet 361, 1258-1265.
156. Thomas P, Hecker J, Faunt J, Fenech M (2007) Buccal micronucleus cytome biomarkers may be associated with Alzheimers disease. Mutagenesis 22, 371-379.
157. Francois M, Leifert W, Hecker J, Faunt J, Martins R, Thomas P, Fenech M (2014) Altered cytological parameters in buccal cells from individuals with mild cognitive impairment and Alzheimers disease. Cytometry A 85, 698-708.
158. Mathur S, Glogowska A, McAvoy E, Righolt C, Rutherford J, Willing C, Banik U, Ruthirakuhan M, Mai S, Garcia A (2014) Three-dimensional quantitative imaging of telomeres in buccal cells identifies mild, moderate, and severe Alzheimers disease patients. J Alzheimers Dis 39, 35-48.
159. Garcia A, Mathur S, Kalaw MC, McAvoy E, Anderson J, Luedke A, Itorralba J, Mai S (2017) Quantitative 3D telomeric imaging of buccal cells reveals Alzheimers disease-specific signatures. J Alzheimers Dis 58, 139-145.
160. Leifert WR, Tuli JF, Francois M, Nguyen T, Rembach A, Rumble RL, Rainey-Smith S, Martins R, Fenech MF (2015) Buccal cell cytokeratin 14 identifies mild cognitive impairment and Alzheimer s disease in the AIBL study of aging. Curr Alzheimer Res 12, 233-241.
161. Leifert WR, Nguyen T, Rembach A, Martins R, Rainey-Smith S, Masters CL, Ames D, Rowe CC, Macaulay SL, Francois M, Fenech MF, Australian Imaging Biomarkers and Lifestyle Research Group (2015) Buccal cell cytokeratin 14 correlates with multiple blood biomarkers of Alzheimers disease risk. J Alzheimers Dis 48, 443-452.
162. Francois M, Fenech MF, Thomas P, Hor M, Rembach A, Martins RN, Rainey-Smith SR, Masters CL, Ames D, Rowe CC, Macaulay SL, Hill AF, Leifert WR, The Australian Imaging Biomarkers and Lifestyle Research Group (2016) High content, multi-parameter analyses in buccal cells to identify Alzheimers disease. Curr Alzheimer Res 13, 787-799.
163. Garcia A, Huang D, Righolt A, Righolt C, Kalaw MC, Mathur S, McAvoy E, Anderson J, Luedke A, Itorralba J, Mai S (2017) Super-resolution structure of DNA significantly differs in buccal cells of controls and Alzheimers patients. J Cell Physiol 232, 2387-2395.
164. Veurink G, Fuller SJ, Atwood CS, Martins RN (2003) Genetics, lifestyle and the roles of amyloid beta and oxidative stress in Alzheimers disease. Ann Hum Biol 30, 639-667.
165. Ferris SH, de Leon MJ, Wolf AP, Farkas T, Christman DR, Reisberg B, Fowler JS, Macgregor R, Goldman A, George AE, Rampal S (1980) Positron emission tomography in the study of aging and senile dementia. Neurobiol Aging 1, 127-131.
166. Ott A, Stolk RP, Hofman A, van Harskamp F, Grobbee DE, Breteler MM (1996) Association of diabetes mellitus and dementia: The Rotterdam Study. Diabetologia 39, 1392-1397.
167. An Y, Varma VR, Varma S, Casanova R, Dammer E, Pletnikova O, Chia CW, Egan JM, Ferrucci L, Troncoso J, Levey AI, Lah J, Seyfried NT, Legido-Quigley C, OBrien R, ThambisettyM(2017) Evidence for brain glucose dysregulation in Alzheimers disease. Alzheimers Dement, doi: 10.1016/j.jalz.2017.09.011
168. Verdile G, Fuller SJ, Martins RN (2015) The role of type 2 diabetes in neurodegeneration. Neurobiol Dis 84, 22-38.
169. Laws SM, Gaskin S, Woodfield A, Srikanth V, Bruce D, Fraser PE, Porter T, Newsholme P, Wijesekara N, Burnham S, Dore V, Li QX, Maruff P, Masters CL, Rainey-Smith S, Rowe CC, Salvado O, Villemagne VL, Martins RN, Verdile G (2017) Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults. Sci Rep 7, 9766.
170. Yang Y, Song W (2013) Molecular links between Alzheimers disease and diabetes mellitus. Neuroscience 250, 140-150.
171. Juranek J, Ray R, Banach M, Rai V (2015) Receptor for advanced glycation end-products in neurodegenerative diseases. Rev Neurosci 26, 691-698.
172. Akash MS, Rehman K, Chen S (2013) Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus. J Cell Biochem 114, 525-531.
173. Rosales-Corral S, Tan DX, Manchester L, Reiter RJ (2015) Diabetes and Alzheimer disease, two overlapping pathologies with the same background: Oxidative stress. OxidMed Cell Longev 2015, 985845.
174. DaulatzaiMA(2017) Cerebral hypoperfusion and glucose hypometabolism: Key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimers disease. J Neurosci Res 95, 943-972.
175. Di Domenico F, Barone E, Perluigi M, Butterfield DA (2017) The triangle of death in Alzheimers disease brain: The aberrant cross-Talk among energy metabolism, mammalian target of rapamycin signaling, and protein homeostasis revealed by redox proteomics. Antioxid Redox Signal 26, 364-387.
176. Butterfield DA, Poon HF, St Clair D, Keller JN, Pierce WM, Klein JB, MarkesberyWR(2006) Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: Insights into the development of Alzheimers disease. Neurobiol Dis 22, 223-232.
177. Ling X, Martins RN, Racchi M, Craft S, Helmerhorst E (2002) Amyloid beta antagonizes insulin promoted secretion of the amyloid beta protein precursor. J Alzheimers Dis 4, 369-374.
178. Xie L, Helmerhorst E, Taddei K, Plewright B, Van Bronswijk W, Martins R (2002) Alzheimers beta-Amyloid peptides compete for insulin binding to the insulin receptor. J Neurosci 22, RC221.
179. Huynh K, Martins RN, Meikle PJ (2017) Lipidomic profiles in diabetes and dementia. J Alzheimers Dis 59, 433-444.
180. Bharadwaj P, Wijesekara N, Liyanapathirana M, Newsholme P, Ittner L, Fraser P, Verdile G (2017) The link between type 2 diabetes and neurodegeneration: Roles for amyloid-beta, amylin, and tau proteins. J Alzheimers Dis 59, 421-432.
181. Czeczor JK, McGee SL (2017) Emerging roles for the amyloid precursor protein and derived peptides in the regulation of cellular and systemic metabolism. J Neuroendocrinol 29, doi: 10.1111/jne.12470
182. Puig KL, Brose SA, Zhou X, Sens MA, Combs GF, Jensen MD, Golovko MY, Combs CK (2017) Amyloid precursor protein modulates macrophage phenotype and diet-dependent weight gain. Sci Rep 7, 43725.
183. Peters KE, Davis WA, Taddei K, Martins RN, Masters CL, Davis TM, Bruce DG (2017) Plasma amyloid-beta peptides in type 2 diabetes: A matched case-control study. J Alzheimers Dis 56, 1127-1133.
184. Maj M, Gartner W, Ilhan A, Neziri D, Attems J, Wagner L (2010) Expression of TAUin insulin-secreting cells and its interaction with the calcium-binding protein secretagogin. J Endocrinol 205, 25-36.
185. MajM, Hoermann G, Rasul S, BaseW, Wagner L, Attems J (2016) The microtubule-Associated protein tau and its relevance for pancreatic beta cells. J Diabetes Res 2016, 1964634.
186. Emoto M, Langille SE, Czech MP (2001) A role for kinesin in insulin-stimulated GLUT4 glucose transporter translocation in 3T3-L1 adipocytes. J Biol Chem 276, 10677-10682.
187. Liu LZ, Cheung SC, Lan LL, Ho SK, Chan JC, Tong PC (2013) Microtubule network is required for insulininduced signal transduction and actin remodeling. Mol Cell Endocrinol 365, 64-74.
188. Miklossy J, Qing H, Radenovic A, Kis A, Vileno B, Laszlo F, Miller L, Martins RN, Waeber G, Mooser V, Bosman F, Khalili K, Darbinian N, McGeer PL (2010) Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes. Neurobiol Aging 31, 1503-1515.
189. Vandal M, White PJ, Tremblay C, St-Amour I, Chevrier G, Emond V, Lefrancois D, Virgili J, Planel E, Giguere Y, Marette A, Calon F (2014) Insulin reverses the high-fat diet-induced increase in brain Abeta and improves memory in an animal model of Alzheimer disease. Diabetes 63, 4291-4301.
190. Wijesekara N, Ahrens R, Sabale M, Wu L, HaK, Verdile G, Fraser PE (2017) Amyloid-beta and islet amyloid pathologies link Alzheimer disease and type 2 diabetes in a transgenic model. FASEB J 31, 5409-5418.
191. Zhang Y, Zhou B, Zhang F, Wu J, Hu Y, Liu Y, Zhai Q (2012) Amyloid-beta induces hepatic insulin resistance by activating JAK2/STAT3/SOCS-1 signaling pathway. Diabetes 61, 1434-1443.
192. Trichopoulou A, Vasilopoulou E (2000) Mediterranean diet and longevity. Br J Nutr 84(Suppl 2), S205-S209.
193. Willcox DC, Scapagnini G, Willcox BJ (2014) Healthy aging diets other than the Mediterranean: A focus on the Okinawan diet. Mech Ageing Dev 136-137, 148-162.
194. Gardener S, Gu Y, Rainey-Smith SR, Keogh JB, Clifton PM, Mathieson SL, Taddei K, Mondal A, Ward VK, Scarmeas N, Barnes M, Ellis KA, Head R, Masters CL, Ames D, Macaulay SL, Rowe CC, Szoeke C, Martins RN, AIBL Research Group (2012) Adherence to a Mediterranean diet and Alzheimers disease risk in an Australian population. Transl Psychiatry 2, e164.
195. Gardener SL, Rainey-Smith SR, Barnes MB, Sohrabi HR, Weinborn M, Lim YY, Harrington K, Taddei K, Gu Y, Rembach A, Szoeke C, Ellis KA, Masters CL, Macaulay SL, Rowe CC, Ames D, Keogh JB, Scarmeas N, Martins RN (2015) Dietary patterns and cognitive decline in an Australian study of ageing. Mol Psychiatry 20, 860-866.
196. Balakrishnan K, Verdile G, Mehta PD, Beilby J, Nolan D, Galvao DA, Newton R, Gandy SE, Martins RN (2005) Plasma Abeta42 correlates positively with increased body fat in healthy individuals. J Alzheimers Dis 8, 269-282.
197. Bates KA, Sohrabi HR, Rainey-Smith SR, Weinborn M, Bucks RS, Rodrigues M, Beilby J, Howard M, Taddei K, Martins G, Paton A, Shah T, Dhaliwal SS, Foster JK, Martins IJ, Lautenschlager NT, Mastaglia FL, Gandy SE, MartinsRN(2017) Serum high-density lipoprotein is associated with better cognitive function in a cross-sectional study of aging women. Int J Neurosci 127, 243-252.
198. FernandoW, Somaratne G, Goozee KG, Williams S, Singh H, Martins RN (2017) Diabetes and Alzheimers disease: Can tea phytochemicals play a role in prevention? J Alzheimers Dis 59, 481-501.
199. Mirmosayyeb O, Tanhaei A, Sohrabi HR, Martins RN, Tanhaei M, Najafi MA, Safaei A, Meamar R (2017) Possible role of common spices as a preventive and therapeutic agent for Alzheimers disease. Int J Prev Med 8, 5.
200. Rainey-Smith SR, Brown BM, Sohrabi HR, Shah T, Goozee KG, Gupta VB, Martins RN (2016) Curcumin and cognition: A randomised, placebo-controlled, doubleblind study of community-dwelling older adults. Br J Nutr 115, 2106-2113.
201. Goozee KG, Shah TM, Sohrabi HR, Rainey-Smith SR, Brown B, Verdile G, Martins RN (2016) Examining the potential clinical value of curcumin in the prevention and diagnosis of Alzheimers disease. Br J Nutr 115, 449-465.
202. Gardener SL, Rainey-Smith SR, Sohrabi HR, Weinborn M, Verdile G, FernandoW, Lim YY, Harrington K, Burnham S, Taddei K, Masters CL, Macaulay SL, Rowe CC, Ames D, Maruff P, Martins RN, AIBL Research Group (2017) Increased carbohydrate intake is associated with poorer performance in verbal memory and attention in an APOE genotype-dependent manner. J Alzheimers Dis 58, 193-201.
203. Fernando WM, Martins IJ, Goozee KG, Brennan CS, Jayasena V, Martins RN(2015) The role of dietary coconut for the prevention and treatment of Alzheimers disease: Potential mechanisms of action. Br J Nutr 114, 1-14.
204. Brown BM, Peiffer JJ, Martins RN (2013) Multiple effects of physical activity on molecular and cognitive signs of brain aging: Can exercise slow neurodegeneration and delay Alzheimers disease? Mol Psychiatry 18, 864-874.
205. Radak Z, Hart N, Sarga L, Koltai E, Atalay M, Ohno H, Boldogh I (2010) Exercise plays a preventive role against Alzheimers disease. J Alzheimers Dis 20, 777-783.
206. Brown BM, Peiffer JJ, Sohrabi HR, Mondal A, Gupta VB, Rainey-Smith SR, Taddei K, Burnham S, Ellis KA, Szoeke C, Masters CL, Ames D, Rowe CC, Martins RN, AIBL Research Group (2012) Intense physical activity is associated with cognitive performance in the elderly. Transl Psychiatry 2, e191.
207. Brown BM, Bourgeat P, Peiffer JJ, Burnham S, Laws SM, Rainey-Smith SR, Bartres-Faz D, Villemagne VL, Taddei K, Rembach A, Bush A, Ellis KA, Macaulay SL, Rowe CC, Ames D, Masters CL, Maruff P, Martins RN, AIBL Research Group (2014) Influence of BDNF Val66Met on the relationship between physical activity and brain volume. Neurology 83, 1345-1352.
208. Brown BM, Sohrabi HR, Taddei K, Gardener SL, Rainey-Smith SR, Peiffer JJ, Xiong C, Fagan AM, Benzinger T, Buckles V, Erickson KI, Clarnette R, Shah T, Masters CL, Weiner M, Cairns N, Rossor M, Graff-Radford NR, Salloway S, Voglein J, Laske C, Noble J, Schofield PR, Bateman RJ, Morris JC, Martins RN, Dominantly Inherited Alzheimer Network (2017) Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimers disease. Alzheimers Dement 13, 1197-1206.
209. Santos-Lozano A, Pareja-Galeano H, Sanchis-Gomar F, Quindos-Rubial M, Fiuza-Luces C, Cristi-Montero C, Emanuele E, Garatachea N, LuciaA(2016) Physical activity and Alzheimer disease: A protective association. Mayo Clin Proc 91, 999-1020.
210. BrayNW, Smart RR, Jakobi JM, JonesGR(2016) Exercise prescription to reverse frailty. Appl Physiol Nutr Metab 41, 1112-1116.
211. Schuch FB, Vancampfort D, Rosenbaum S, Richards J, Ward PB, Veronese N, Solmi M, Cadore EL, Stubbs B (2016) Exercise for depression in older adults: A metaanalysis of randomized controlled trials adjusting for publication bias. Rev Bras Psiquiatr 38, 247-254.
212. Northey JM, Cherbuin N, Pumpa KL, Smee DJ, Rattray B (2018) Exercise interventions for cognitive function in adults older than 50: A systematic review with metaanalysis. Br J Sports Med 52, 154-160.
213. Brown BM, Rainey-Smith SR, Bucks RS, Weinborn M, Martins RN (2016) Exploring the bi-directional relationship between sleep and beta-Amyloid. Curr Opin Psychiatry 29, 397-401.
214. Potvin O, Lorrain D, Forget H, Dube M, Grenier S, Preville M, Hudon C (2012) Sleep quality and 1-year incident cognitive impairment in community-dwelling older adults. Sleep 35, 491-499.
215. Sterniczuk R, Theou O, Rusak B, Rockwood K (2013) Sleep disturbance is associated with incident dementia and mortality. Curr Alzheimer Res 10, 767-775.
216. Shi L, Chen SJ, Ma MY, Bao YP, Han Y, Wang YM, Shi J, Vitiello MV, Lu L (2017) Sleep disturbances increase the risk of dementia: A systematic review and meta-Analysis. Sleep Med Rev, doi: 10.1016/j.smrv. 2017.06.010
217. Brown BM, Rainey-Smith SR, Villemagne VL, Weinborn M, Bucks RS, Sohrabi HR, Laws SM, Taddei K, Macaulay SL, Ames D, Fowler C, Maruff P, Masters CL, Rowe CC, Martins RN, AIBL Research Group (2016) The relationship between sleep quality and brain amyloid burden. Sleep 39, 1063-1068.
218. Xiao M, Hu G (2014) Involvement of aquaporin 4 in astrocyte function and neuropsychiatric disorders. CNS Neurosci Ther 20, 385-390.
219. Petit D, Montplaisir J, Lorrain D, Gauthier S (1992) Spectral analysis of the rapid eye movement sleep electroencephalogram in right and left temporal regions: A biological marker of Alzheimers disease. Ann Neurol 32, 172-176.
220. Pike CJ (2017) Sex and the development of Alzheimers disease. J Neurosci Res 95, 671-680.
221. Wang YQ, Qu DH, Wang K (2016) Therapeutic approaches to Alzheimers disease through stimulating of non-Amyloidogenic processing of amyloid precursor protein. Eur Rev Med Pharmacol Sci 20, 2389-2403.
222. Henderson VW (2014) Alzheimers disease: Review of hormone therapy trials and implications for treatment and prevention after menopause. J Steroid Biochem Mol Biol 142, 99-106.
223. Burkhardt MS, Foster JK, Laws SM, Baker LD, Craft S, Gandy SE, Stuckey BG, Clarnette R, Nolan D, Hewson-Bower B, Martins RN (2004) Oestrogen replacement therapy may improve memory functioning in the absence of APOE epsilon4. J Alzheimers Dis 6, 221-228.
224. Fuller SJ, Tan RS, Martins RN (2007) Androgens in the etiology of Alzheimers disease in aging men and possible therapeutic interventions. J Alzheimers Dis 12, 129-142.
225. Drummond ES, Harvey AR, Martins RN (2009) Androgens and Alzheimers disease. Curr Opin Endocrinol Diabetes Obes 16, 254-259.
226. Lv W, Du N, Liu Y, Fan X, Wang Y, Jia X, Hou X, Wang B (2016) Low testosterone level and risk of Alzheimers disease in the elderly men: A systematic review and metaanalysis. Mol Neurobiol 53, 2679-2684.
227. Treanor CJ, Li J, Donnelly M (2017) Cognitive impairment among prostate cancer patients: An overview of reviews. Eur J Cancer Care (Engl) 26, doi: 10.1111/ecc. 12642
228. Verdile G, Laws SM, Henley D, Ames D, Bush AI, Ellis KA, Faux NG, Gupta VB, Li QX, Masters CL, Pike KE, Rowe CC, Szoeke C, Taddei K, Villemagne VL, Martins RN, AIBL Research Group (2014) Associations between gonadotropins, testosterone and beta amyloid in men at risk of Alzheimers disease. Mol Psychiatry 19, 69-75.
229. Asih PR, Wahjoepramono EJ, Aniwiyanti V, Wijaya LK, de Ruyck K, Taddei K, Fuller SJ, Sohrabi H, Dhaliwal SS, Verdile G, Carruthers M, Martins RN (2015) Testosterone replacement therapy in older male subjective memory complainers: Double-blind randomized crossover placebo-controlled clinical trial of physiological assessment and safety. CNS Neurol Disord Drug Targets 14, 576-586.
230. Wahjoepramono EJ, Asih PR, Aniwiyanti V, Taddei K, Dhaliwal SS, Fuller SJ, Foster J, Carruthers M, Verdile G, Sohrabi HR, MartinsRN(2016) The effects of testosterone supplementation on cognitive functioning in older men. CNS Neurol Disord Drug Targets 15, 337-343.
231. Barron AM, Verdile G, Martins RN (2006) The role of gonadotropins in Alzheimers disease: Potential neurodegenerative mechanisms. Endocrine 29, 257-269.
232. Verdile G, Yeap BB, Clarnette RM, Dhaliwal S, Burkhardt MS, Chubb SA, De Ruyck K, Rodrigues M, Mehta PD, Foster JK, Bruce DG, Martins RN (2008) Luteinizing hormone levels are positively correlated with plasma amyloid-beta protein levels in elderly men. J Alzheimers Dis 14, 201-208.
233. Rodrigues MA, Verdile G, Foster JK, Hogervorst E, Joesbury K, Dhaliwal S, Corder EH, Laws SM, Hone E, Prince R, Devine A, Mehta P, Beilby J, Atwood CS, Martins RN (2008) Gonadotropins and cognition in older women. J Alzheimers Dis 13, 267-274.
234. Burnham V, Sundby C, Laman-Maharg A, Thornton J (2017) Luteinizing hormone acts at the hippocampus to dampen spatial memory. Horm Behav 89, 55-63.
235. Blair JA, Palm R, Chang J, McGee H, Zhu X, Wang X, Casadesus G (2016) Luteinizing hormone downregulation but not estrogen replacement improves ovariectomy-Associated cognition and spine density loss independently of treatment onset timing. Horm Behav 78, 60-66.
236. Verdile G, Asih PR, Barron AM, Wahjoepramono EJ, Ittner LM, Martins RN (2015) The impact of luteinizing hormone and testosterone on beta amyloid (Abeta) accumulation: Animal and human clinical studies. Horm Behav 76, 81-90.